MagForce : to participate in nine upcoming international conferences in H2 2018
September 03, 2018 at 08:05 am EDT
Share
DGAP-News: MagForce AG / Key word(s): Conference
MagForce AG to participate in nine upcoming international conferences in H2 2018
03.09.2018 / 14:00
The issuer is solely responsible for the content of this announcement.
MagForce AG to participate in nine upcoming international conferences in H2 2018
Berlin, Germany and Nevada, USA, September 3, 2018 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its participation in nine upcoming scientific and investor conferences in the second half of 2018:
Geman Fall Conference
Date: September 3-4, 2018
Location: Frankfurt, Germany
Presentation: Christian von Volkmann, CFO of MagForce AG, Tuesday, September 4, 2018
Goldman Sachs European Medtech and Healthcare Conference
Date: September 5-6, 2018
Location: London, UK
Presentation: Ben J. Lipps, CEO of MagForce AG, Thursday, September 6, 2018
Berenberg & Goldman Sachs Seventh German Corporate Conference
Date: September 24-26, 2018
Location: Munich, Germany
Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, September 25, 2018
13th Meeting of the European Association of Neuro-Oncology (EANO 2018)
Date: October 10-14, 2018
Location: Stockholm, Sweden
18th European Congress of Neurosurgery (EANS 2018)
Date: October 21-25, 2018
Location: Brussels, Belgium
Booth: No. 12
Lunch Symposium: "Local Therapies For Malignant Gliomas"
Speakers: Prof Dr Walter Stummer, Director of the Department of Neurosurgery at the University Hospital Muenster, Germany;
Colin Watts, MD PHD, University of Birmingham, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, Birmingham, Great Britain
Date & Time: Golden Hall, Tuesday, October 23, 2018; 1.15-2.15pm CEST
MEDICA 2018
Date: November 12-15, 2018
Location: Düsseldorf, Germany
Community booth: Berlin Partner für Wirtschaft und Technologie GmbH No. F 42, hall 15
23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO)
Date: November 15-18, 2018
Location: New Orleans, Louisiana, USA
German Equity Forum 2018
Date: November 26-28, 2018
Location: Frankfurt, Germany
Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, November 27, 2018
Prior Capital Market Conference
Date: December 4, 2018
Location: Dreieich, Germany
Presentation: Barbara von Frankenberg, Vice President Communications & Investor Relations of MagForce AG, Tuesday, December 4, 2018
About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.
NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.
For more information, please visit: www.magforce.com. Get to know our Technology: video (You Tube)
Disclaimer This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.
Contact:
Barbara von Frankenberg
Vice President
Communications & Investor Relations
T +49-30-308380-77
E-Mail: bfrankenberg@magforce.com
03.09.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Magforce AG is a Germany-based company engaged in the provision of nanotechnology solutions for health sector. Its non-invasive technology uses magnetic nanoparticles to combat tumors, without harmful effect on the healthy tissues. The Company's range of treatment products includes NanoTherm Therapie for treating tumors locally; NanoTherm, a fluid containing ferrous oxide molecules that penetrate deeply into the tumor tissues and reacting to the presence of a magnetic field; NanoActivator, which are iron oxide nanoparticles for tumors in all areas of the body, and NanoPlan, a software platform that facilitates therapy planning and adjusts proper temperatures for the treatment and and the necessary magnetic field strength. As of December 31, 2011, Nanostart AG held a 49.6%-stake in the Company.
MAGFORCE AG 
